Crossmark

Treatment-related serious adverse events and fatal adverse events with regorafenib in cancer patients: a meta-analysis of phase 3 randomized controlled trials

Crossref DOI link: https://doi.org/10.1007/s10637-017-0512-6

Published Online: 2017-09-22

Published Print: 2017-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Cao, Meihui

Li, Feifei

Wang, Yue

Zhang, Jingdong https://orcid.org/0000-0001-9037-7554
License Information

Text and Data Mining valid from 2017-09-22

Version of Record valid from 2017-09-22
More Information

Article History

Received: 26 July 2017

Accepted: 14 September 2017

First Online: 22 September 2017

Compliance with ethical standards

:

: Meihui Cao declares that she has no conflict of interest. Feifei Li declares that she has no conflict of interest. Yue Wang declares that he has no conflict of interest. Jingdong Zhang declares that he has no conflict of interest.

: This article does not contain any studies with human participants or animals performed by any of the authors.

Document is current

Any future updates will be listed below